Idelalisib is a targeted therapy medicine that has a protein called P3K (phosphatidyloinositil 3 kinase) used in the treatment of Follicular Lymphoma (FL) and CLL. Idelalisib works by stopping the P3K enzyme in the body which is over active in some B cell lymphomas driving the cells to multiply, move to other areas and survive.
Idelalisib is an oral tablet you take every day. Idelalisib may have the following side effects;
Altered liver function tests
Diarrhoea, fever and rash
Idelalisib is approved by the TGA for the following indications;
Follicular Lymphoma as a third line treatment
CLL/SLL as a first line treatment with a 17p deletion or TP53 mutation
CLL/SLL as a second line treatment in combination with an anti CD20 immunotherapy medicineIdelalisib